Response to 'How to define disease severity accurately in patients with familial Mediterranean fever'
Rheumatol Int
.
2021 Jan;41(1):239-240.
doi: 10.1007/s00296-020-04656-8.
Epub 2020 Jul 25.
Authors
Nuray Aktay Ayaz
1
,
Ayşe Tanatar
2
,
Şerife Gül Karadağ
3
,
Mustafa Çakan
4
,
Gonca Keskindemirci
5
,
Hafize Emine Sönmez
3
Affiliations
1
Department of Pediatric Rheumatology, Istanbul University Medical School, Fatih, Istanbul, Turkey. nurayaktay@gmail.com.
2
Department of Pediatric Rheumatology, Istanbul University Medical School, Fatih, Istanbul, Turkey.
3
Department of Pediatric Rheumatology, University of Health Sciences, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Turkey.
4
Department of Pediatric Rheumatology, University of Health Sciences, Zeynep Kamil Research and Training Hospital, Istanbul, Turkey.
5
Department of Pediatrics, Istanbul University Medical School, Istanbul, Turkey.
PMID:
32712707
DOI:
10.1007/s00296-020-04656-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Child
Colchicine
Familial Mediterranean Fever* / diagnosis
Familial Mediterranean Fever* / drug therapy
Genotype
Humans
Phenotype
Severity of Illness Index
Substances
Colchicine